Pheon Therapeutics

Antibody drug conjugate
#Antibodies #Antibody drug conjugate (ADC) #Cancer research #Funding #Pheon Therapeutics #Solid tumours

$120m raised to develop differentiated ADC pipeline 

Pheon Therapeutics has completed a $120m Series B financing to fund the development of its pipeline of next generation ADCs for a wide range of hard-to-treat cancers.  The new financing will be used to further advance Pheon’s differentiated ADC pipeline through clinical proof of concept. The first three assets are… Read More

#Business & Investment #Cancer Research #News

Cancer Abnormal Cells Nucleus Genetic Division Infection Microscope
#Antibody drug conjugate (ADC) #Biocytogen Pharmaceuticals #License agreement #Pheon Therapeutics #Therapeutic Antibodies

Licence agreement to develop ADCs for hard-to-treat cancers 

Pheon Therapeutics, an antibody drug conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, has entered an exclusive licence agreement with Biocytogen Pharmaceuticals, a global biotech company focused on the discovery of novel antibody therapeutics.   Under the terms of the agreement, Pheon… Read More

#News